JP2014532766A - 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 - Google Patents

癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 Download PDF

Info

Publication number
JP2014532766A
JP2014532766A JP2014541256A JP2014541256A JP2014532766A JP 2014532766 A JP2014532766 A JP 2014532766A JP 2014541256 A JP2014541256 A JP 2014541256A JP 2014541256 A JP2014541256 A JP 2014541256A JP 2014532766 A JP2014532766 A JP 2014532766A
Authority
JP
Japan
Prior art keywords
compound
formula
bone
maleate
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014541256A
Other languages
English (en)
Japanese (ja)
Inventor
デーナ ティー． アフタブ，
デーナ ティー． アフタブ，
フラウケ シュモラー，
フラウケ シュモラー，
Original Assignee
エクセリクシス， インク．
エクセリクシス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス， インク．, エクセリクシス， インク． filed Critical エクセリクシス， インク．
Publication of JP2014532766A publication Critical patent/JP2014532766A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
JP2014541256A 2011-11-08 2012-11-08 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 Pending JP2014532766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557358P 2011-11-08 2011-11-08
US61/557,358 2011-11-08
PCT/US2012/064116 WO2013070890A1 (en) 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017193945A Division JP2018048154A (ja) 2011-11-08 2017-10-04 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤

Publications (1)

Publication Number Publication Date
JP2014532766A true JP2014532766A (ja) 2014-12-08

Family

ID=47179011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014541256A Pending JP2014532766A (ja) 2011-11-08 2012-11-08 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
JP2017193945A Pending JP2018048154A (ja) 2011-11-08 2017-10-04 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017193945A Pending JP2018048154A (ja) 2011-11-08 2017-10-04 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤

Country Status (15)

Country Link
US (1) US20140323522A1 (enExample)
EP (1) EP2776033A1 (enExample)
JP (2) JP2014532766A (enExample)
KR (1) KR20140088610A (enExample)
CN (1) CN104159585A (enExample)
AU (2) AU2012335737A1 (enExample)
BR (1) BR112014011009A2 (enExample)
CA (1) CA2854336A1 (enExample)
EA (1) EA201490944A1 (enExample)
HK (1) HK1202062A1 (enExample)
IL (1) IL232421A0 (enExample)
IN (1) IN2014CN04067A (enExample)
MX (1) MX2014005458A (enExample)
TW (2) TWI662962B (enExample)
WO (1) WO2013070890A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515988A (ja) * 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
JP2019531354A (ja) * 2016-10-18 2019-10-31 ベイジン コンルンス ファーマシューティカル カンパニー リミテッド キノリル置換カルボン酸化合物又はその薬学的に許容される塩、その薬物組成物及び使用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
TW201309650A (zh) 2011-02-10 2013-03-01 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EP2704717A1 (en) 2011-05-02 2014-03-12 Exelixis, Inc. Method of treating cancer and bone cancer pain
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
CN105503717A (zh) * 2014-09-24 2016-04-20 江苏奥赛康药业股份有限公司 一种苹果酸卡博替尼化合物及其药物组合物
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537916A (ja) * 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537916A (ja) * 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Trial of Cabozantinib(XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone", CLINICALTRIALS. GOV. ARCHIVE, JPN6017010521, 1 September 2011 (2011-09-01), ISSN: 0003526328 *
D. C. SMITH ET AL.: "Phase 2 study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC", J CLIN ONCOL, vol. 29(7), JPN6016034807, 1 April 2011 (2011-04-01), pages 7 - 127, ISSN: 0003396621 *
D. C. SMITH ET AL: "Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC", EJC SUPPLEMENT, JPN6016034806, 18 November 2010 (2010-11-18), pages 129, ISSN: 0003396620 *
IDRUGS, vol. 13, no. 2, JPN6016034809, 2010, pages 112 - 121, ISSN: 0003396623 *
M HUSSAIN ET AL.: "Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phas", J CLIN ONCOL, vol. 29, JPN6016034808, June 2011 (2011-06-01), pages 4516, ISSN: 0003396622 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515988A (ja) * 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
JP2019531354A (ja) * 2016-10-18 2019-10-31 ベイジン コンルンス ファーマシューティカル カンパニー リミテッド キノリル置換カルボン酸化合物又はその薬学的に許容される塩、その薬物組成物及び使用

Also Published As

Publication number Publication date
AU2012335737A1 (en) 2014-06-05
CA2854336A1 (en) 2013-05-16
EA201490944A1 (ru) 2014-10-30
CN104159585A (zh) 2014-11-19
US20140323522A1 (en) 2014-10-30
EP2776033A1 (en) 2014-09-17
HK1202062A1 (en) 2015-09-18
MX2014005458A (es) 2015-04-16
TW201818937A (zh) 2018-06-01
IL232421A0 (en) 2014-06-30
TWI662962B (zh) 2019-06-21
KR20140088610A (ko) 2014-07-10
AU2017225103A1 (en) 2017-09-28
IN2014CN04067A (enExample) 2015-10-23
TW201322981A (zh) 2013-06-16
JP2018048154A (ja) 2018-03-29
BR112014011009A2 (pt) 2017-06-06
WO2013070890A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
JP2018048154A (ja) 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
US20240156803A1 (en) Method of Treating Cancer
JP6884528B2 (ja) 癌および骨癌疼痛の治療方法
US9861624B2 (en) Method of treating cancer
TW201323864A (zh) 定量癌症治療之方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206